Defining the relationship between COPD and CVD: what are the implications for clinical practice?

Therapeutic Advances in Respiratory Disease

Volumn 12, Issue , 2018, Pages

  Morgan, Ann D ^a   Zakeri, Rosita ^a   Quint, Jennifer K ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

cardiovascular disease comorbidities; cardiovascular disease risk management; chronic obstructive pulmonary disease; COPD

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT;

AGING; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COMORBIDITY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EARLY INTERVENTION; EVIDENCE BASED MEDICINE; HEALTH ECONOMICS; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPOXIA; INCIDENCE; INFLAMMATION; LENGTH OF STAY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK MANAGEMENT; SMOKING; AGED; CARDIOVASCULAR SYSTEM; FEMALE; LUNG; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

AGED; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; LUNG; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 85053940429     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465817750524     Document Type: Article

References (100)

1. Divo M, Cote C, de Torres JP. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155–161
2. Berry CE, Wise RA., Mortality in COPD: causes, risk factors, and prevention. COPD 2010; 7: 375–382
3. Decramer M, Janssens W., Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013; 1: 73–83
4. Maclay JD, MacNee W., Cardiovascular disease in COPD: mechanisms. Chest 2013; 143: 798–807
5. Roversi S, Fabbri LM, Sin DD. Chronic obstructive pulmonary disease and cardiac diseases: an urgent need for integrated care. Am J Respir Crit Care Med 2016; 194: 1319–1336
6. Sin DD, Man SFP. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514–1519
7. Fabbri LM., Smoking, not COPD, as the disease. N Engl J Med 2016; 374: 1885–1886
8. Rabe KF, Watz H., Chronic obstructive pulmonary disease. Lancet 2017; 389: 1931–1940
9. Adeloye D, Chua S, Lee C. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health 2015; 5: e020415
10. Public Health England. Public Health Profiles: Inhale - INteractive Health Atlas of Lung conditions in England. London: Public Health England, http://fingertips.phe.org.uk/ (accessed February 2017)
11. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5: 691–706
12. Barnett K, Mercer SW, Norbury M. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 37–43
13. Vanfleteren LE, Spruit MA, Groenen M. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728–735
14. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2017 Report). 2017: Global Initiative for Chronic Obstructive Pulmonary Disease, http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ (accessed 15 November 2017)
15. Baty F, Putora PM, Isenring B. Comorbidities and burden of COPD: a population based case-control study. PLoS One 2013; 8: e63285
16. Lange P, Mogelvang R, Marott JL. Cardiovascular morbidity in COPD: a study of the general population. COPD 2011; 7: 5–10
17. Chen W, Thomas J, Sadatsafavi M. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015; 3: 631–639
18. Aryal S., Prevalence of COPD and comorbidity. In: Rabe KF, Wedzicha JA, Wouters EFM, (eds) COPD and comorbidity. Monographs vol. 59. European Respiratory Society; 2013: 1–12
19. Müllerova H, Agusti A, Erqou S. Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013; 144: 1163–1178
20. Lahousse L, Tiemeier H, Ikram MA. Chronic obstructive pulmonary disease and cerebrovascular disease: a comprehensive review. Respir Med 2015; 109: 1371–1380
21. Morgan AD, Sharma C, Rothnie KJ. Chronic obstructive pulmonary disease and the risk of stroke. Ann Am Thorac Soc 2017; 14: 754–765
22. Houben-Wilke S, Jörres RA, Bals R. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences–Comorbidities Network Study. Am J Respir Crit Care Med 2017; 195: 189–197
23. Pinto LM, Alghamdi M, Benedetti A. Derivation and validation of clinical phenotypes for COPD: a systematic review. Respir Res 2015; 16: 50
24. Camiciottoli G, Bigazzi F, Magni C. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2016; 11: 2229–2236
25. Takahashi S, Betsuyaku T., The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries. Respir Investig 2015; 53: 259–270
26. Franssen FME, Soriano JB, Roche N. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med 2016; 194: 568–576
27. Bhatt SP, Dransfield MT., Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013; 162: 237–251
28. Feary JR, Rodrigues LC, Smith CJ. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956–962
29. Maclay JD, MacNee W., Assessment of cardiovascular comorbidity. In: Rabe KF, Wedzicha JA, Wouters EFM, (eds) COPD and comorbidity. Monographs vol. 59. European Respiratory Society; 2013: 28–49
30. Rothnie KJ, Yan R, Smeeth L. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open 2015; 5: e007824
31. Portegies ML, Lahousse L, Joos GF. Chronic obstructive pulmonary disease and the risk of stroke. The Rotterdam study. Am J Respir Crit Care Med 2015; 193: 251–258
32. Yin L., Differential association of chronic obstructive disease with myocardial infarction and ischemic stroke in a nation-wide cohort. Int J Cardiology 2014: 140: 601–603
33. Curkendall SM, DeLuise C, Jones JK. Cardiovascular disease in patients with chronic obstructive pulmonary disease: Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63–70
34. Agarwal SK, Heiss G, Barr RG. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail 2012; 14: 414–422
35. Goudis CA., Chronic obstructive pulmonary disease and atrial fibrillation: an unknown relationship. J Cardiol 2017; 69: 699–705
36. Pujades-Rodriguez M, George J, Shah AD. Heterogeneous associations between smoking and a wide range of initial presentations of cardiovascular disease in 1937360 people in England: lifetime risks and implications for risk prediction. Int J Epidemiol 2015; 44: 129–141
37. Engstrom G, Hedblad B, Janzon L. Respiratory decline in smokers and ex-smokers–an independent risk factor for cardiovascular disease and death. J Cardiovasc Risk 2000; 7: 267–272
38. Tockman MS, Pearson JD, Fleg JL. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med 1995; 151: 390–398
39. Anthonisen NR, Connett JE, Kiley JP. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497–1505
40. Sidney S, Sorel M, Quesenberry CP, Jr. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–2075
41. Gershon AS, Mecredy GC, Guan J. Quantifying comorbidity in individuals with COPD: a population study. Eur Respir J 2015; 45: 51–59
42. Patel ARC, Donaldson GC, Mackay AJ. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012; 141: 851–857
43. Sin DD, Anthonisen NR, Soriano JB. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245–1257
44. Stone IS, Barnes NC, Petersen SE., Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart 2012; 98: 1055–1062
45. Mannino DM, Thorn D, Swensen A. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962–969
46. Rothnie KJ, Smeeth L, Herrett E. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart 2015; 101: 1103–1110
47. Mills NL, Miller JJ, Anand A. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax 2008; 63: 306–311
48. Libby P., Inflammation in atherosclerosis. Nature 2002; 420: 868–874
49. Paulus WJ, Tschope C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263–271
50. Gan WQ, Man SF, Senthilselvan A. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574–580
51. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; 27: 902–907
52. Hurst JR, Donaldson GC, Perera WR. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867–874
53. Roversi S, Roversi P, Spadafora G. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest 2014; 44: 93–102
54. Celli BR, Locantore N, Yates J. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1065–1072
55. Man SF, Connett JE, Anthonisen NR. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61: 849–853
56. Marchetti N, Ciccolella DE, Jacobs MR. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD 2011; 8: 60–65
57. Criner GJ, Connett JE, Aaron SD. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370: 2201–2210
58. John ME, Cockcroft JR, McKeever TM. Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a randomized controlled trial. Int J Chron Obstruct Pulmon Dis 2015; 10: 211–221
59. Barnes PJ., Senescence in COPD and its comorbidities. Annu Rev Physiol 2016; 79: 517–539
60. Savale L, Chaouat A, Bastuji-Garin S. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 566–571
61. Tsuji T, Aoshiba K, Nagai A., Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 2006; 174: 886–893
62. Tuder RM, Yoshida T, Fijalkowka I. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc Am Thorac Soc 2006; 3: 673–679
63. Benetos A, Okuda K, Lajemi M. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension 2001; 37: 381–385
64. Minamino T, Miyauchi H, Yoshida T. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105: 1541–1544
65. Maclay JD, McAllister DA, Rabinovich R. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax 2012; 67: 606–612
66. Sciurba FC, Rogers RM, Keenan RJ. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996; 334: 1095–1099
67. Falk JA, Martin UJ, Scharf S. Lung elastic recoil does not correlate with pulmonary hemodynamics in severe emphysema. Chest 2007; 132: 1476–1484
68. Kida Y, Goligorsky MS., Sirtuins, cell senescence, and vascular aging. Can J Cardiol 2016; 32: 634–641
69. Vanfleteren LE, Spruit MA, Groenen MT. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J 2014; 43: 1306–1315
70. Vlachopoulos C, Aznaouridis K, Stefanadis C., Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318–1327
71. Vivodtzev I, Tamisier R, Baguet JP. Arterial stiffness in COPD. Chest 2014; 145: 861–875
72. Austin V, Crack Peter J, Bozinovski S. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci 2016; 130: 1039–1050
73. Cohen AJ, Brauer M, Burnett R. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet 2017; 389: 1907–1918
74. Wright JL, Petty T, Thurlbeck WM., Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 1992; 170: 109–124
75. Dinh-Xuan AT, Higenbottam TW, Clelland CA. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324: 1539–1547
76. Chen R, Lin L, Tian JW. Predictors of dynamic hyperinflation during the 6-minute walk test in stable chronic obstructive pulmonary disease patients. J Thorac Dis 2015; 7: 1142–1150
77. Lahousse L, Verhamme KM, Stricker BH. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med 2016; 4: 149–164
78. Heindl S, Lehnert M, Criee CP. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med 2001; 164: 597–601
79. Donohue JF, Hanania NA, Make B. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest 2014; 146: 1531–1542
80. ®) in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis 2015; 10: 239–259
81. Dong YH, Lin HH, Shau WY. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 2013; 68: 48–56
82. Gershon A, Croxford R, Calzavara A. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013; 173: 1175–1185
83. Vestbo J, Anderson JA, Brook RD. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387: 1817–1826
84. Calverley PMA, Anderson JA, Brook RD. Fluticasone furoate, vilanterol and lung function decline in patients with moderate COPD and heightened cardiovascular risk. Am J Respir Crit Care Med. Epub ahead of print 24 July 2017. DOI: 10.1164/rccm.201610-2086OC
85. Brook RD, Anderson JA, Calverley PM. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart 2017; 103: 1536–1542
86. Agustí A, Noell G, Brugada J. Lung function in early adulthood and health in later life: a transgenerational cohort analysis. Lancet Respir Med 2017; 5: 935–945
87. Bhatt SP, Wells JM, Dransfield MT., Cardiovascular disease in COPD: a call for action. Lancet Respir Med 2014; 2: 783–785
88. Quint JK, Herrett E, Bhaskaran K. Effect of beta blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013; 347: f6650
89. Lipworth B, Wedzicha J, Devereux G. Beta-blockers in COPD: time for reappraisal. Eur Respir J 2016; 48: 880–888
90. Bakke PS., Cormorbities in current COPD guidelines. In: Rabe KF, Wedzicha JA, Wouters EFM, (eds) COPD and comorbidity. Monographs vol. 59. European Respiratory Society; 2013: 217–222
91. Vanfleteren LE, Spruit MA, Wouters EF. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med 2016; 4: 911–924
92. MacDonald MI, Shafuddin E, King PT. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 2016; 4: 138–148
93. van der Molen T. Co-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequences. Prim Care Respir J 2010; 19: 326–334
94. Piscaer I, Wouters EFM, Vermeer C. Vitamin K deficiency: the linking pin between COPD and cardiovascular diseases? Respir Res 2017; 18: 189
95. Parikh MA, Aaron CP, Hoffman EA. Angiotensin-converting inhibitors and angiotensin II receptor blockers and longitudinal change in percent emphysema on computed tomography. The multi-ethnic study of atherosclerosis lung study. Ann Am Thorac Soc 2017; 14: 649–658
96. Polverino F, Laucho-Contreras ME, Petersen H. A pilot study linking endothelial injury in lungs and kidneys in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; 195: 1464–1476
97. Polverino F, Celli BR, Owen CA., Chronic obstructive pulmonary disease: breathing new life into old cardiovascular drugs? Ann Am Thorac Soc 2017; 14: 1718
98. Zhang W, Zhang Y, Li C-W. Effect of statins on COPD. Chest. Epub ahead of print 25 August 2017. DOI: 10.1016/j.chest.2017.08.015
99. Rinne ST, Liu CF, Wong ES. Organizational structure for chronic heart failure and chronic obstructive pulmonary disease. Am J Manage Care 2016; 22: e82–e87
100. National Institute for Health and Care Excellence. Multimorbidity: assessment, prioritisation and management of care for people with commonly occurring multimorbidity. NICE Guideline NG56, September 2016. London, UK: National Institute for Health and Care Excellence